As global stocks of remdesivir, one of the few promising therapeutic drugs for COVID-19, are becoming scarcer, drug maker Gilead Sciences says voluntary licensing to allow more manufacturers to produce the drug will not help expand access, which is in the minds of supporters. „I expect Remdesivir to be available worldwide at the same time if the evidence continues to support the use of Remdesivir in the treatment of COVID 19. Global launches are a common practice in the pharmaceutical industry. According to Peter Liese, this is not fast enough and threatens to introduce the compulsory license, which means that the drug would be produced by others against the will of gilead. The Member stated that this was technically feasible because the company had to provide all the necessary production details in its patent application file. Gilead has experienced well-deserved outrage since the announcement of a 3,120 $US price tag to insurers for Remdesivir, with prices slightly lower than 2340 $US for U.S. government buyers and buyers in other developed countries. For a drug with no proven benefits for survival, which has received huge public subsidies, and which can be produced at an estimated cost of $5.58 (for a five-day treatment) and which is already sold for only $400 per generic, Gilead has a lot of nerves. In addition to his nerves, Gilead has shown ridiculous and ridiculous favoritism after 60% of his initial donations re-taught delivered to the United States and now almost every next three months of production, 500,000 doses, in the United States, leaving any other country in the world in the cold. And despite Gilead`s view that Remdesivir`s current price is „significantly lower” than its market value, civil society supporters and health ministers find it inaccessible to many people.
Supporters argued that Remdesivir could be taken into account even less, since the current market price is five times higher than that of production, according to estimates in the Journal of Virus Eradication. Under the licensing agreements, companies are entitled to transfer technology from Gilead`s manufacturing process to Remdesivir so that their production can be revived more quickly. Licensees also set their own prices for the generic drug they produce. Licenses are exempt from licence until the World Health Organization declares an end to the Covid-19 public health emergency, or until a drug other than remedivir or a vaccine for the treatment or prevention of COVID-19 is authorized, depending on the previous date.